Cases & Deals

Jefferies International, Kempen, and KBC complete €42 million share placing by Ablynx

Clients Jefferies International Limited, KBC Securities NV, and Kempen & Co N.V.

Jones Day represented Jefferies International Limited, KBC Securities NV, and Kempen & Co N.V. in connection with the sale of shares in an accelerated book build placing by Ablynx NV, a biotechnology company focused on the discovery and development of a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments for a range of serious human diseases including inflammation, haematology, oncology, and pulmonary disease.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.